Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STING1 | Q86WV6 | 1/20 | 0.45 |
| ▸ | NT5E | P21589 | 1/20 | 0.45 |
| ▸ | FUT5 | Q11128 | 1/20 | 0.43 |
| ▸ | RNASEL | Q05823 | 4/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | DTYMK | P23919 | 2/20 | 0.43 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.42 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26067592 | 0.89 | NT5E (0.58) | NT5EFUT5RNASELTAS1R3TAS1R1 | |
| SCHEMBL26067602 | 0.89 | NT5E (0.58) | NT5EFUT5RNASELTAS1R3TAS1R1 | |
| SCHEMBL22352078 | 0.88 | RNASEL (0.52) | NT5ERNASEL | |
| SCHEMBL20326954 | 0.88 | STING1 (0.47) | STING1NT5E | |
| SCHEMBL20324534 | 0.88 | STING1 (0.47) | STING1NT5E | |
| SCHEMBL26067692 | 0.85 | DNPH1 (0.63) | NT5ERNASELTAS1R3TAS1R1 | |
| SCHEMBL23476786 | 0.84 | STING1 (0.46) | STING1 | |
| SCHEMBL22268153 | 0.84 | RNASEL (0.55) | RNASEL | |
| SCHEMBL22268152 | 0.84 | RNASEL (0.55) | RNASEL | |
| SCHEMBL22083745 | 0.84 | F2 (0.47) | STING1FUT5POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230250127-A1 | MODIFIED mRNA 5'-CAP ANALOGS | Nanjing GeneLeap Biotechnology Co., Ltd. (CN) | 2023-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230250127-A1 | MODIFIED mRNA 5'-CAP ANALOGS | RNGTT, RNMT, NSUN2 | STING1 761/4885NT5E 338/4885FUT5 1640/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.